At this point, approximately 2.5 years into the clinical trials, more than 5,000 patients have been enrolled in phase II and III clinical trials, Dr. Druker told his audience. Researchers have observed no dose-limiting toxicity. Common side effects include nausea, muscle cramps, periorbital edema, and myelosuppression. By inhibiting tyrosine kinase, the drug helps to restore chemotherapeutic sensitivity. Glivec has shown efficacy in an early trial involving gastrointestinal stromal tumors, Dr. Druker added.
Plans are also underway to test the drug against small cell lung cancer and glioblastoma.
Glivec manufacturer Novartis Pharmaceuticals submitted its application for approval to the US Food and Drug Administration in February. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.